Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Genotype-phenotype correlations in pediatric patients with myotonic dystrophy type 1

  • Kim, Hyeong Jung (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Na, Ji-Hoon (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Lee, Young-Mock (Department of Pediatrics, Yonsei University College of Medicine)
  • 투고 : 2018.08.28
  • 심사 : 2018.09.20
  • 발행 : 2019.02.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Myotonic dystrophy, also known as dystrophia myotonica (DM), is an autosomal dominant disorder with 2 genetically distinct forms. DM type 1 (DM1) is the more common form and is caused by abnormal expansion of cytosine/thymine/guanine (CTG) repeats in the DM protein kinase (DMPK ) gene. Our study aimed to determine whether the age of onset is correlated with CTG repeat length in a population of pediatric patients with DM1. Methods: We retrospectively identified 30 pediatric patients with DM1 that underwent DMPK testing, of which the clinical data of 17 was sufficient. The cohort was divided into 2 subgroups based on the clinical phenotype (congenital-onset vs. late-onset) and number of CTG repeats (<1,000 vs. ${\geq}1,000$). Results: We found no significant difference between the age of onset and CTG repeat length in our pediatric patient population. Based on clinical subgrouping, we found that the congenital-onset subgroup was statistically different with respect to several variables, including prematurity, rate of admission to neonatal intensive care unit, need for respiratory support at birth, hypotonia, dysphagia, ventilator dependence, and functional status on last visit, compared to the late-onset subgroup. Based on genetic subgrouping, we found a single variable (poor feeding in neonate) that was significantly different in the large CTG subgroup than that in the small CTG subgroup. Conclusion: Clinical variables exhibiting statistically significant differences between the subgroups should be focused on prognosis and designing tailored management approaches for the patients; our findings will contribute to achieve this important goal for treating patients with DM1.

키워드

참고문헌

  1. De Vivo DC, Ryan MM, Jones HR, Darras BT. Neuromuscular disorders of infancy, childhood, and adolescence: a clinician's approach. 2nd ed. Amsterdam: Academic Press, 2014.
  2. Musova Z, Mazanec R, Krepelova A, Ehler E, Vales J, Jaklova R, et al. Highly unstable sequence interruptions of the CTG repeat in the myotonic dystrophy gene. Am J Med Genet A 2009;149A:1365-74. https://doi.org/10.1002/ajmg.a.32987
  3. Harper PS, Brook JD, Newman E. Myotonic dystrophy. 3rd ed. London: WB Saunders, 2001.
  4. Bundey S, Carter CO, Soothill JF. Early recognition of heterozygotes for the gene for dystrophia myotonica. J Neurol Neurosurg Psychiatry 1970;33:279-93. https://doi.org/10.1136/jnnp.33.3.279
  5. Pizzuti A, Friedman DL, Caskey CT. The myotonic dystrophy gene. Arch Neurol 1993;50:1173-9. https://doi.org/10.1001/archneur.1993.00540110053005
  6. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992;255:1253-5. https://doi.org/10.1126/science.1546325
  7. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992;68:799-808. https://doi.org/10.1016/0092-8674(92)90154-5
  8. Arsenault ME, Prevost C, Lescault A, Laberge C, Puymirat J, Mathieu J. Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions. Neurology 2006;66:1248-50. https://doi.org/10.1212/01.wnl.0000208513.48550.08
  9. Harley HG, Rundle SA, MacMillan JC, Myring J, Brook JD, Crow S, et al. Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet 1993;52:1164-74.
  10. Kim SY, Kim JY, Kim GP, Sung JJ, Lim KS, Lee KW, et al. Molecular and clinical characteristics of myotonic dystrophy type 1 in koreans. Korean J Lab Med 2008;28:483-92. https://doi.org/10.3343/kjlm.2008.28.6.483
  11. Kahrizi K, Moradin N, Azimian M, Shojasaffar B, Alavi K, Nafiisi S, et al. Genotype-phenotype correlations in Iranian myotonic dystrophy type I patients. Iran Rehabil J 2010;8:8-12.
  12. De Antonio M, Dogan C, Hamroun D, Mati M, Zerrouki S, Eymard B, et al. Unravelling the myotonic dystrophy type 1 clinical spectrum: a systematic registry-based study with implications for disease classification. Rev Neurol (Paris) 2016;172:572-80. https://doi.org/10.1016/j.neurol.2016.08.003
  13. Willaert A, Jorissen M, Goeleven A. Swallowing dysfunction in myotonic dystrophy: a retrospective study of symptomatology and radiographic findings. B-ENT 2015;11:249-56.
  14. Thil C, Agrinier N, Chenuel B, Poussel M. Longitudinal course of lung function in myotonic dystrophy type 1. Muscle Nerve 2017;56:816-8. https://doi.org/10.1002/mus.25604
  15. Hamshere MG, Harley H, Harper P, Brook JD, Brookfield JF. Myotonic dystrophy: the correlation of (CTG) repeat length in leucocytes with age at onset is significant only for patients with small expansions. J Med Genet 1999;36:59-61.
  16. Savic D, Rakocvic-Stojanovic V, Keckarevic D, Culjkovic B, Stojkovic O, Mladenovic J, et al. 250 CTG repeats in DMPK is a threshold for correlation of expansion size and age at onset of juvenile-adult DM1. Hum Mutat 2002;19:131-9. https://doi.org/10.1002/humu.10027
  17. Kurihara T. New classification and treatment for myotonic disorders. Intern Med 2005;44:1027-32. https://doi.org/10.2169/internalmedicine.44.1027
  18. Smith CA, Gutmann L. Myotonic dystrophy type 1 management and therapeutics. Curr Treat Options Neurol 2016;18:52. https://doi.org/10.1007/s11940-016-0434-1
  19. Hanns L, Chris T. PhenoDM1 - Myotonic Dystrophy type 1 (DM1) deep phenotyping to improve delivery of personalised medicine and assist in the planning, design and recruitment of clinical trials. Clinical Trials.gov. NCT02831504. Bethesda (MD): U.S. National Library of Medicine, 2016

피인용 문헌

  1. Impact of prematurity and the CTG repeat length on outcomes in congenital myotonic dystrophy vol.13, 2020, https://doi.org/10.1186/s13104-020-05186-z